Deutsche Bank AG Purchases Shares of 190,914 Avantor, Inc. $AVTR

Deutsche Bank AG bought a new stake in Avantor, Inc. (NYSE:AVTR) during the second quarter, HoldingsChannel reports. The firm bought 190,914 shares of the company’s stock, valued at approximately $1,890,000.

Several other institutional investors and hedge funds have also bought and sold shares of AVTR. Private Management Group Inc. grew its position in shares of Avantor by 50.4% during the 4th quarter. Private Management Group Inc. now owns 2,456,859 shares of the company’s stock worth $28,156,000 after buying an additional 823,572 shares in the last quarter. GSA Capital Partners LLP purchased a new stake in Avantor in the second quarter worth about $800,000. Oppenheimer Asset Management Inc. purchased a new stake in Avantor in the second quarter worth about $805,000. Assenagon Asset Management S.A. grew its holdings in Avantor by 425.0% during the 2nd quarter. Assenagon Asset Management S.A. now owns 556,871 shares of the company’s stock worth $5,513,000 after acquiring an additional 450,801 shares in the last quarter. Finally, Brickwood Asset Management LLP grew its holdings in Avantor by 6,891.9% during the 4th quarter. Brickwood Asset Management LLP now owns 3,184,043 shares of the company’s stock worth $36,489,000 after acquiring an additional 3,138,504 shares in the last quarter. Institutional investors own 95.08% of the company’s stock.

Analyst Upgrades and Downgrades

AVTR has been the subject of several research reports. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a $13.00 price target on shares of Avantor in a research report on Thursday, July 30th. Wells Fargo & Company lifted their price objective on shares of Avantor from $14.00 to $16.00 and gave the company an “overweight” rating in a report on Thursday, July 30th. Jefferies Financial Group raised shares of Avantor from an “underperform” rating to a “hold” rating and set a $13.00 price objective for the company in a research note on Wednesday, July 29th. Royal Bank Of Canada upped their target price on Avantor from $9.00 to $14.00 and gave the stock a “sector perform” rating in a report on Thursday, July 30th. Finally, Wolfe Research raised Avantor from a “strong sell” rating to a “hold” rating in a research report on Thursday, July 30th. Two research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Avantor presently has a consensus rating of “Hold” and a consensus target price of $12.00.

Avantor Stock Down 0.1%

Shares of AVTR stock opened at $14.60 on Friday. The stock’s fifty day moving average price is $12.12 and its 200 day moving average price is $9.77. Avantor, Inc. has a 1-year low of $7.26 and a 1-year high of $15.93. The company has a market cap of $9.87 billion, a price-to-earnings ratio of -17.38, a price-to-earnings-growth ratio of 11.03 and a beta of 0.89. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.78 and a quick ratio of 1.18.

Avantor (NYSE:AVTR) last released its quarterly earnings results on Wednesday, July 29th. The company reported $0.21 EPS for the quarter, beating analysts’ consensus estimates of $0.19 by $0.02. Avantor had a positive return on equity of 9.92% and a negative net margin of 8.81%.The company had revenue of $1.69 billion during the quarter, compared to analysts’ expectations of $1.61 billion. During the same period last year, the business posted $0.24 earnings per share. The firm’s revenue was up .5% compared to the same quarter last year. Avantor has set its FY 2026 guidance at 0.800-0.830 EPS. On average, research analysts expect that Avantor, Inc. will post 0.81 earnings per share for the current fiscal year.

Avantor Profile

Avantor, Inc (NYSE:AVTR) is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company delivers essential solutions that support research, development, production and safety applications. Its product portfolio spans from high-purity chemicals and reagents to biologics and cell culture media, as well as lab equipment, consumables and custom manufacturing services.

Avantor’s offerings are organized across two primary segments.